抗レトロウイルス薬へのアクセス、男性 (%)の世界ランキング2000〜2022年【国別順位】
2000〜2022年の抗レトロウイルス薬へのアクセス、男性 (%)について、各国の世界ランキングを表形式にして、国別順位をまとめました。
2022年の1位はクウェートで94、2位はジンバブエで93、3位はコモロで92でした。
HIV とともに生存し、抗レトロウイルス療法を受けている成人男性の割合。
【英語版はこちら】
抗レトロウイルス薬へのアクセス、男性 (%)の国別の推移グラフ【2000〜2022年】
抗レトロウイルス薬へのアクセス、男性 (%)
抗レトロウイルス薬へのアクセス、男性 (%)の世界ランキング 2022
表示年度: 2022年
-
+
| 順位 | 国 | 抗レトロウイルス薬へのアクセス、男性 (%) | 前年比 | |
|---|---|---|---|---|
| 検索: | ||||
| 1 | 94 | 10.59% | ||
| 2 | 93 | 3.33% | ||
| 3 | 92 | 8.24% | ||
| 3 | 92 | 9.52% | ||
| 3 | 92 | |||
| 3 | 92 | 9.52% | ||
| 7 | 91 | 2.25% | ||
| 7 | 91 | 30.00% | ||
| 9 | 90 | 13.92% | ||
| 9 | 90 | 5.88% | ||
| 11 | 89 | 2.30% | ||
| 12 | 88 | 1.15% | ||
| 12 | 88 | 7.32% | ||
| 12 | 88 | 8.64% | ||
| 15 | 87 | 6.10% | ||
| 15 | 87 | 12.99% | ||
| 15 | 87 | 12.99% | ||
| 15 | 87 | 4.82% | ||
| 19 | 86 | 1.18% | ||
| 19 | 86 | 6.17% | ||
| 21 | 85 | 2.41% | ||
| 22 | 84 | 10.53% | ||
| 22 | 84 | 5.00% | ||
| 22 | 84 | 1.20% | ||
| 25 | 83 | 3.75% | ||
| 25 | 83 | |||
| 27 | 82 | 10.81% | ||
| 28 | 81 | 2.53% | ||
| 28 | 81 | 5.19% | ||
| 28 | 81 | 2.53% | ||
| 31 | 80 | 2.56% | ||
| 31 | 80 | 1.27% | ||
| 33 | 79 | 6.76% | ||
| 33 | 79 | 12.86% | ||
| 35 | 78 | 14.71% | ||
| 36 | 76 | 1.33% | ||
| 37 | 75 | 10.29% | ||
| 37 | 75 | 4.17% | ||
| 39 | 74 | 7.25% | ||
| 39 | 74 | 1.37% | ||
| 41 | 73 | 8.96% | ||
| 41 | 73 | 19.67% | ||
| 43 | 72 | -4.00% | ||
| 44 | 71 | 4.41% | ||
| 44 | 71 | 2.90% | ||
| 44 | 71 | |||
| 47 | 70 | 9.38% | ||
| 47 | 70 | -1.41% | ||
| 49 | 69 | 4.55% | ||
| 49 | 69 | 2.99% | ||
| 49 | 69 | 9.52% | ||
| 49 | 69 | 25.45% | ||
| 49 | 69 | -1.43% | ||
| 54 | 68 | 7.94% | ||
| 54 | 68 | 19.30% | ||
| 54 | 68 | 3.03% | ||
| 57 | 67 | 45.65% | ||
| 57 | 67 | 8.06% | ||
| 57 | 67 | 4.69% | ||
| 60 | 66 | 3.12% | ||
| 60 | 66 | 6.45% | ||
| 60 | 66 | 24.53% | ||
| 63 | 65 | 3.17% | ||
| 64 | 64 | 3.23% | ||
| 64 | 64 | 8.47% | ||
| 64 | 64 | -1.54% | ||
| 67 | 63 | -3.08% | ||
| 67 | 63 | 3.28% | ||
| 67 | 63 | |||
| 67 | 63 | 3.28% | ||
| 67 | 63 | 1.61% | ||
| 72 | 62 | -1.59% | ||
| 73 | 61 | |||
| 73 | 61 | 3.39% | ||
| 73 | 61 | 8.93% | ||
| 76 | 60 | 13.21% | ||
| 77 | 59 | 5.36% | ||
| 77 | 59 | 9.26% | ||
| 79 | 58 | 9.43% | ||
| 79 | 58 | 3.57% | ||
| 81 | 57 | 5.56% | ||
| 82 | 56 | 9.80% | ||
| 82 | 56 | 9.80% | ||
| 82 | 56 | 24.44% | ||
| 85 | 54 | 1.89% | ||
| 85 | 54 | 3.85% | ||
| 87 | 53 | 6.00% | ||
| 87 | 53 | 10.42% | ||
| 87 | 53 | |||
| 90 | 52 | 10.64% | ||
| 91 | 49 | 11.36% | ||
| 92 | 48 | 11.63% | ||
| 92 | 48 | 17.07% | ||
| 94 | 47 | 14.63% | ||
| 94 | 47 | 14.63% | ||
| 96 | 46 | |||
| 97 | 45 | 4.65% | ||
| 97 | 45 | 2.27% | ||
| 99 | 44 | 7.32% | ||
| 100 | 43 | 16.22% | ||
| 100 | 43 | 7.50% | ||
| 102 | 42 | 5.00% | ||
| 102 | 42 | 5.00% | ||
| 104 | 40 | 14.29% | ||
| 104 | 40 | -4.76% | ||
| 104 | 40 | 8.11% | ||
| 107 | 39 | 21.88% | ||
| 107 | 39 | |||
| 107 | 39 | 11.43% | ||
| 107 | 39 | 11.43% | ||
| 111 | 38 | -7.32% | ||
| 112 | 37 | 8.82% | ||
| 113 | 36 | 20.00% | ||
| 114 | 32 | 14.29% | ||
| 115 | 30 | |||
| 116 | 28 | -15.15% | ||
| 117 | 26 | |||
| 117 | 26 | 18.18% | ||
| 119 | 25 | 25.00% | ||
| 120 | 24 | |||
| 121 | 23 | 15.00% | ||
| 122 | 11 | 22.22% | ||
| 123 | 9 | |||